While novel hormonal therapies (NHT) have revolutionized androgen deprivation therapy (ADT) for metastatic castration-sensitive prostate cancer (mCSPC), the optimal intensification of treatment remains a challenge.
While novel hormonal therapies (NHT) have revolutionized androgen deprivation therapy (ADT) for metastatic castration-sensitive prostate cancer (mCSPC), the optimal intensification of treatment remains a challenge.
BROADCASTMED